First Trust Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.01M Sell
27,466
-476,069
-95% -$22.6M ﹤0.01% 2156
2025
Q4
$25.6M Buy
503,535
+461,940
+1,111% +$23.6M 0.02% 805
2025
Q3
$2.31M Sell
41,595
-19,903
-32% -$1.17M ﹤0.01% 1769
2025
Q2
$4.24M Sell
61,498
-30,873
-33% -$2.1M ﹤0.01% 1439
2025
Q1
$6.41M Sell
92,371
-487,282
-84% -$40.2M 0.01% 1203
2024
Q4
$49.9M Buy
579,653
+518,361
+846% +$56.1M 0.04% 513
2024
Q3
$7.3M Sell
61,292
-331,128
-84% -$44.2M 0.01% 1158
2024
Q2
$56M Sell
392,420
-119,812
-23% -$15.9M 0.06% 406
2024
Q1
$65.8M Buy
512,232
+441,343
+623% +$52.5M 0.07% 372
2023
Q4
$7.33M Sell
70,889
-81,256
-53% -$8.04M 0.01% 1107
2023
Q3
$13.8M Buy
152,145
+7,611
+5% +$670K 0.02% 880
2023
Q2
$11.7M Sell
144,534
-154,550
-52% -$12.6M 0.01% 961
2023
Q1
$23.8M Buy
299,084
+184,808
+162% +$13.1M 0.03% 673
2022
Q4
$7.73M Sell
114,276
-1,225,232
-91% -$71.8M 0.01% 1036
2022
Q3
$66.7M Buy
1,339,508
+1,335,810
+36,122% +$71.6M 0.09% 341
2022
Q2
$206K Sell
3,698
-1,109,810
-100% -$61.6M ﹤0.01% 2382
2022
Q1
$61.8M Sell
1,113,508
-2,220
-0.2% -$114K 0.06% 452
2021
Q4
$62.5M Sell
1,115,728
-69,366
-6% -$3.76M 0.06% 439
2021
Q3
$56.9M Sell
1,185,094
-251,332
-17% -$12.2M 0.06% 430
2021
Q2
$60.1M Sell
1,436,426
-212,852
-13% -$8.25M 0.07% 414
2021
Q1
$55.6M Buy
1,649,278
+139,298
+9% +$4.96M 0.07% 424
2020
Q4
$52.7M Sell
1,509,980
-27,796
-2% -$961K 0.07% 407
2020
Q3
$53.4M Buy
1,537,776
+168,438
+12% +$5.61M 0.09% 330
2020
Q2
$44.8M Buy
1,369,338
+29,088
+2% +$928K 0.08% 369
2020
Q1
$40.3M Sell
1,340,250
-331,248
-20% -$9.86M 0.09% 364
2019
Q4
$48.4M Buy
1,671,498
+1,663,698
+21,329% +$46.1M 0.08% 384
2019
Q3
$202K Sell
7,800
-676
-8% -$17.1K ﹤0.01% 2338
2019
Q2
$216K Buy
+8,476
New +$209K ﹤0.01% 2344
2019
Q1
Sell
-40,666
Closed -$937K 2443
2018
Q4
$937K Sell
40,666
-980,870
-96% -$21.8M ﹤0.01% 1856
2018
Q3
$24.1M Buy
1,021,536
+88,274
+9% +$2.15M 0.04% 538
2018
Q2
$21.5M Buy
933,262
+913,966
+4,737% +$21.7M 0.04% 536
2018
Q1
$475K Sell
19,296
-38,452
-67% -$1.01M ﹤0.01% 2035
2017
Q4
$1.55M Buy
57,748
+20,456
+55% +$520K ﹤0.01% 1660
2017
Q3
$898K Sell
37,292
-63,754
-63% -$1.44M ﹤0.01% 1886
2017
Q2
$2.17M Sell
101,046
-1,046,276
-91% -$21.1M 0.01% 1431
2017
Q1
$19.7M Buy
1,147,322
+296,158
+35% +$5.16M 0.05% 490
2016
Q4
$15.3M Buy
851,164
+251,522
+42% +$4.56M 0.05% 574
2016
Q3
$12.5M Buy
599,642
+574,646
+2,299% +$14.2M 0.04% 644
2016
Q2
$672K Sell
24,996
-23,184
-48% -$636K ﹤0.01% 1865
2016
Q1
$1.3M Buy
48,180
+13,348
+38% +$358K ﹤0.01% 1542
2015
Q4
$1.01M Sell
34,832
-52,668
-60% -$1.46M ﹤0.01% 1736
2015
Q3
$2.37M Buy
87,500
+31,782
+57% +$900K 0.01% 1314
2015
Q2
$1.53M Buy
55,718
+32,232
+137% +$906K ﹤0.01% 1648
2015
Q1
$627K Buy
+23,486
New +$541K ﹤0.01% 1910
2014
Q4
Sell
-11,824
Closed -$282K 2294
2014
Q3
$282K Sell
11,824
-28,926
-71% -$666K ﹤0.01% 2060
2014
Q2
$941K Buy
40,750
+6,286
+18% +$139K ﹤0.01% 1716
2014
Q1
$787K Buy
34,464
+6,074
+21% +$129K ﹤0.01% 1778
2013
Q4
$525K Sell
28,390
-1,720
-6% -$30K ﹤0.01% 1878
2013
Q3
$510K Buy
+30,110
New +$506K ﹤0.01% 1899

Other funds holding NVO

First Trust Advisors's NVO Position: Q1 2026 in Review

First Trust Advisors reduced its Novo Nordisk (NVO) stake by 95% in Q1 2026, selling an estimated $22.6M and leaving 27,466 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

First Trust Advisors first reported a position in NVO in Q3 2013 and has held it in 49 quarters since. The position peaked at $66.7M in Q3 2022. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • First Trust Advisors held 27,466 shares of Novo Nordisk worth $1.01M as of Q1 2026.
  • First Trust Advisors sold 476,069 Novo Nordisk shares in Q1 2026, an estimated $22.6M.
  • Novo Nordisk made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #2156 holding.
  • First Trust Advisors first reported a position in Novo Nordisk in Q3 2013 and has held it in 49 quarters since.
  • First Trust Advisors's Novo Nordisk position peaked at $66.7M in Q3 2022.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.